
More interest in a new approach to CAR-T cells
In order to create cell therapies using the first-in-class humanised antibody BNC101, Australian CAR-T cell specialist Carina Biotech has entered into a deal with Bionomics Limited. Carina will fund all R&D and pay up to A$118 million ($86 million) in clinical and development milestones, under the terms of the global, exclusive agreement. Bionomics will also…